ANJ810: MCL1 Inhibitor
MCL1 is a member of the Bcl-2 family, normally acting as a “brake” on the apoptosis pathway.
Anji Onco, a subsidiary of Anji Pharma, is laser-focused on blocking escape routes cancer uses to evade therapeutic intervention. These survival mechanisms - from amplifying a gene that promotes cancer survival, to displaying proteins that cloak cancer cells and hide them from the immune system - diminish the efficacy of even the most powerful anti-cancer drugs. Our unwavering belief is that resistance can be overcome.